Showing 7131-7140 of 8649 results for "".
- Richard Lindstrom, MD, to Lead Eye Care Biopharmaceutical Company Surface Ophthalmicshttps://modernod.com/news/richard-lindstrom-md-to-lead-new-eye-care-biopharmaceutical-company-surface-ophthalmics/2482161/Surface Ophthalmics announced the appointment of Richard Lindstrom, MD, as Founder and Chairman. Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, PA. Dr. Lindstrom will lead in partnership with Surface’s Board of Directors, including
- MediPrint Ophthalmics Completes Phase 2b Study of Drug-Eluting Contact Lens for Glaucomahttps://modernod.com/news/mediprint-ophthalmics-completion-phase-2b-study-of-drug-eluting-contact-lens-for-glaucoma/2482158/MediPrint Ophthalmics announced it has completed its SIGHT-2 phase 2b study evaluating its lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution. LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens leveraging com
- The Vision Council’s Membership Base to Include Healthcare, Technology, and Contact Lens Companieshttps://modernod.com/news/the-vision-councils-membership-base-to-include-healthcare-technology-and-contact-lens-companies/2482157/The Vision Council has expanded its membership structure to include healthcare, technology, and contact lens companies, according to a company news release. "With guidance from our Board of Directors to ensure that The Vision Council is both reflective of our evolving industry
- SDC Transitions its Ophthalmic Biometric Division to Ora Inc.https://modernod.com/news/sdc-transitions-its-ophthalmic-biometric-division-to-ora-inc/2482149/Statistics & Data Corporation (SDC) has decided to transition its ophthalmic biometric division to its partner Ora Inc. Since 2005, SDC’s partnership and common ownership with Ora has provided clinical trial services in ophthalmology, while allowing S
- Neurolenses Demonstrate Headache Relief in New Studyhttps://modernod.com/news/neurolenses-demonstrate-headache-relief-in-new-study/2482145/Neurolens announced results of a company-sponsored study evaluating the impact of Neurolens prescription lenses on individuals with headaches. The six-item Headache Impact Test (H
- Study: Blindness from Some Inherited Eye Diseases May be Caused by Gut Bacteriahttps://modernod.com/news/study-blindness-from-some-inherited-eye-diseases-may-be-caused-by-gut-bacteria/2482140/Sight loss in certain inherited eye diseases may be caused by gut bacteria, and is potentially treatable by antimicrobials, according to a new study in mice co-led by a University College London (UCL) and Moorf
- Nicox Names New CEO; Restructures Debt to Focus on NCX 470 Pivotal Trialhttps://modernod.com/news/nicox-names-new-ceo-restructures-debt-to-focus-on-ncx-470-pivotal-trial/2482137/Nicox announced this week that its Board of Directors has promoted Gavin Spencer to Chief Executive Officer. He previously served as Executive Vice-President, Chief Business Officer & Head of Corporate Development. Mr. Gavin will be replacing Andreas Segerros, whose mandat
- Palitin Misses Co-Primary Endpoints in Phase 3 Dry Eye Disease Trialhttps://modernod.com/news/palitin-misses-co-primary-endpoints-in-phase-3-trial-dry-eye-disease-candidate/2482136/Palatin Technologies did not achieve statistical significance in the co-primary endpoints of its pivotal phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED). MELODY-1 had two co-primary efficacy endpoints
- UC Irvine Study Shows Similarities and Differences in Human and Insect Vision Formationhttps://modernod.com/news/uc-irvine-study-shows-similarities-and-differences-in-human-and-insect-vision-formation/2482129/Researchers at the University of California, Irvine have discovered similarities and surprising differences between humans and insects in the production of the light-absorbing molecule of the retina, 11-cis-retinal, also known as the “visual chromophore,” according to a UC Irvine news
- SightGlass Vision Receives FDA Breakthrough Device Designation for Myopia Spectacle Lenshttps://modernod.com/news/sightglass-vision-receives-fda-breakthrough-device-designation/2482118/The FDA has granted Breakthrough Device designation to SightGlass Vision's Diffusion Optics Technology (DOT) spectacle lenses, which are intended to slow myopia progression in children. The design is the first to use the contrast management mechanism of action, incorporating thousan